New hope for rare immune disorder: emapalumab studied in chinese patients
NCT ID NCT05744063
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study looked at how safe and effective emapalumab is for Chinese patients with primary hemophagocytic lymphohistiocytosis (pHLH), a rare and serious immune disorder. Thirteen patients who had already received treatment were given emapalumab. The main goal was to see how many had to stop the drug due to side effects, and the study also measured how well the drug controlled the disease. The results help doctors understand how to use this medicine in this specific group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Swedish Orphan Biovitrum Research site
Shanghai, Fudan, China
-
Swedish Orphan Biovitrum Research site
Beijing, Xicheng, China
-
Swedish Orphan Biovitrum Research site
Beijing, China
-
Swedish Orphan Biovitrum Research site
Chongqing, China
-
Swedish Orphan Biovitrum Research site
Guangzhou, China
-
Swedish Orphan Biovitrum Research site
Nanjing, China
-
Swedish Orphan Biovitrum Research site
Zhengzhou, China
Conditions
Explore the condition pages connected to this study.